Announcing the First Nonstimulant Approved for Adult ADHD in 20 Years1

Qelbree™ (viloxazine extended-release capsules) logo with dosing information

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.


In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Tuesday, June 14, 2022


Greg Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine

President Elect, The American Professional Society of
ADHD and Related Disorders (APSARD)

President, Midwest Research Group
St Louis, MO

Theresa R. Cerulli, MD

Medical Director
Cerulli and Associates
North Andover, MA

Lecturer/Clinical Supervisor
Beth Israel Deaconess Medical Center
Boston, MA

Andrew Cutler, MD

Clinical Associate Professor of Psychiatry
SUNY Upstate Medical University

Chief Medical Officer
Neuroscience Education Institute
Lakewood Ranch, FL



Register now to reserve your spot in one of these
live national broadcast events!


Find a live venue near you

Please enter in your zip code.

Can’t make it to a live event?

Link in to participate via the live webcast.

Register for Webcast

Greg Mattingly, MD

Associate Clinical Professor,
Washington University
President, Midwest
Research Group
Board of Directors, APSARD
Editorial Board, Journal of
​Attention Disorders

Ann Childress, MD

Center for Psychiatry and
Behavioral Medicine, Inc
Las Vegas, NV

Andrew J. Cutler, MD

Associate Clinical Professor
SUNY Upstate Medical University
Lakewood Ranch, FL